Systemic treatment for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new prom...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Manushi, Arain, Abeer, Jin, Zhaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Medical Association 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160617/
https://www.ncbi.nlm.nih.gov/pubmed/30276361
http://dx.doi.org/10.1016/j.cdtm.2018.08.003
Descripción
Sumario:Hepatocellular carcinoma (HCC) is one of the most common cancers with high mortality worldwide. Treatment options for patients with advanced stage HCC remain a great challenge. However, novel agents especially small molecule tyrosine kinase inhibitor and innovative immunotherapy demonstrate new promising therapeutic options for these patients. This review article summarizes systemic treatment options evaluated in HCC focusing on the most recently published data and ongoing studies.

Ejemplares similares